Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Despite the plethora of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is disappointing. There is considerable evidence that the quality of reporting of studies of biomarkers, particularly tumor prognostic markers, is generally poor. McShaneet al. present guidelines that provide helpful suggestions on study design, patient characteristics, statistical analysis methods, and guidance on how to present data. The authors advocate the importance of transparent and complete reporting of tumor marker prognostic studies in order to increase accessibility and interpretability of trial data, which should help to improve patient treatment and management.